2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1800

Objectively Measured Sedentary Behavior Is a Distinct Risk Factor from Low Moderate-to-Vigorous Activity in Predicting Subsequent Frailty: Evidence from Osteoarthritis Initiative
Abstract Number: 544

Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis
Abstract Number: 2016

Occupation and Risk of Developing Rheumatoid Arthritis
Abstract Number: 2534

Ocular Surface Temperature in Early Sjogren’s Syndrome and Established Disease
Abstract Number: 2268

Odanacatib Anti-Fracture Efficacy and Safety in Postmenopausal Women with Osteoporosis: Results from the Phase III Long-Term Odanacatib Fracture Trial
Abstract Number: 2119

Off Work Days Decreased RATE in Muskuloeskeletal Disease Patients: Usefulness of the EARLY Intervention Program
Abstract Number: 1288

Older Adults with Osteoarthritis Do Not Have an Increased Risk of Cognitive Impairment
Abstract Number: 1118

Olecranon Bursitis Is Often Hemorrhagic and Responds to Steroid Injections
Abstract Number: 2409

Omega-3 Fatty Acids and Mediterranean Diet As Complimentary Therapies for Rheumatoid Arthritis
Abstract Number: 133

On-Demand Ultrasonography Assessment in the Most Affected Joint Is Efficient for Management of RA Patients in Daily Practice
Abstract Number: 1048

Oncostatin M Suppresses Activation of IL-17/Th17 Via Suppressor of Cytokine signaling3 (SOCS3) Regulation in CD4+ T Cells
Abstract Number: 1797

One-Year Survival of Adults with Systemic Sclerosis Following Lung Transplantation: A Nationwide Cohort Study
Abstract Number: 2324

Only 30% Rheumatologists Collect Basdai in Patients with Axial Spa in Daily Practice: The Potential Role of a Consensual Meeting to Improve It
Abstract Number: 646

ONO-4059 – a Highly Potent and Dual Oral Inhibitor of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase: Improves Anti-Nuclear Antibodies–mediated SLE in Mice
Abstract Number: 244

Onset, Magnitude, and Durability of Pain Relief in Patients with Knee OA Receiving a Fixed-Dose Combination Tablet of Enteric-Coated (EC) Naproxen Plus Immediate-Release (IR) Esomeprazole Magnesium Versus Celecoxib and Placebo: Pooled Results from Two Randomized Controlled Trials

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].